Abstract
Osimertinib is associated with a relatively high frequency of interstitial lung disease (ILD). On the other hand, the occurrence of transient asymptomatic pulmonary opacities (TAPO) has been reported. In clinical setting, the frequency of TAPO and the pros and cons of osimertinib continuation is not clearly known.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
